Alx Oncology Holdings annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Alx Oncology Holdings Depreciation & Amortization Growth & History (ALXO)
Alx Oncology Holdings's depreciation and amortization was $706,000 for fiscal 2025.
View full Alx Oncology Holdings company overviewAlx Oncology Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $706,000 | −$166,000 | −19.04% |
| 2024 | 2024-12-31 | $872,000 | $36,000 | +4.31% |
| 2023 | 2023-12-31 | $836,000 | $494,000 | +144.44% |
| 2022 | 2022-12-31 | $342,000 | $291,000 | +570.59% |
| 2021 | 2021-12-31 | $51,000 | −$151,000 | −74.75% |
| 2020 | 2020-12-31 | $202,000 | −$227,000 | −52.91% |
| 2019 | 2019-12-31 | $429,000 | −$2,000 | −0.46% |
| 2018 | 2018-12-31 | $431,000 | — | — |
Alx Oncology Holdings quarterly depreciation and amortization
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $100,000 | −$100,000 | −50.00% |
| Q1 2026 | 2026-03-31 | $150,000 | −$61,000 | −28.91% |
| Q4 2025 | 2025-12-31 | $151,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $200,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $211,000 | −$3,000 | −1.40% |
| Q3 2024 | 2024-09-30 | $200,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $200,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $214,000 | $1,000 | +0.47% |
| Q3 2023 | 2023-09-30 | $200,000 | $100,000 | +100.00% |
| Q2 2023 | 2023-06-30 | $200,000 | $100,000 | +100.00% |
| Q1 2023 | 2023-03-31 | $213,000 | $155,000 | +267.24% |
| Q3 2022 | 2022-09-30 | $100,000 | $100,000 | — |
| Q2 2022 | 2022-06-30 | $100,000 | $100,000 | — |
| Q1 2022 | 2022-03-31 | $58,000 | $53,000 | +1060.00% |
| Q3 2021 | 2021-09-30 | $0 | −$100,000 | — |
| Q2 2021 | 2021-06-30 | $0 | −$100,000 | — |
| Q1 2021 | 2021-03-31 | $5,000 | −$108,000 | −95.58% |
| Q3 2020 | 2020-09-30 | $100,000 | $0 | 0.00% |
| Q2 2020 | 2020-06-30 | $100,000 | $0 | 0.00% |
| Q1 2020 | 2020-03-31 | $113,000 | — | — |
| Q3 2019 | 2019-09-30 | $100,000 | — | — |
| Q2 2019 | 2019-06-30 | $100,000 | — | — |
Alx Oncology Holdings depreciation and amortization trends
Over the last five fiscal years, Alx Oncology Holdings's depreciation and amortization increased from $202,000 to $706,000, a change of $504,000. The latest reported quarter, Q2 2026, shows $100,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alx Oncology Holdings source filings ↗